Model-Informed Drug Development in the Age of AI
Lorem ipsum dolor sit amet consectetur. Donec diam risus volutpat tempor. Massa accumsan aliquam nibh…
CertaraMarch 10, 2025
Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach
This study explores a model-based meta-analysis (MBMA) and a clinical utility index (CUI) approach to…
CertaraMarch 4, 2025
Machine Learning for PK/PD Modeling in Drug Development
Pharmacometricians can use machine learning for PK/PD modeling to help them characterize the safety and…
CertaraMarch 4, 2025
The Unrealized Potential of Advanced Modeling Methods to Inform Early Strategic Planning for Payer Reimbursement
This article explores the overlooked yet critical role of early strategic planning for payer reimbursement…
CertaraFebruary 25, 2025
Pharmacometrics Drug Development Decision Support: Model-Based Meta-Analysis (MBMA)
Whether you’re optimizing trial design or seeking strategic insights, Certara’s MBMA delivers the clarity and…
CertaraFebruary 19, 2025
Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling
Today’s drug candidates are more complex than ever. But with development decisions on the line,…
CertaraFebruary 12, 2025
Machine Learning for Population PK Model Selection: Theory and Practice
Three of Certara's expert modelers provide a gentle introduction to machine learning in our field.…
CertaraFebruary 7, 2025
Simcyp Version 24: Advancing PBPK capabilities and translating new science and technology into regulatory-accepted predictive modeling
With the release of Version 24, the Simcyp Simulator introduces cutting-edge enhancements that further elevate…
CertaraFebruary 7, 2025
Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies
This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…
CertaraFebruary 6, 2025
